Group Highlights
Group revenue increased by 16% to $738 million, driven by the very strong performance of our Injectables business in the first half
Group adjusted operating margin rose to 33.2%, up from 29.6%, reflecting a higher Injectables margin
Profit attributable to shareholders increased by 132% to $169 million. On an adjusted basis, profit attributable to shareholders rose 44% to $176 million
Basic EPS increased 130% to 85.4 cents per share
Net cash flow from operating activities increased by $64 million to $200 million
Completed the acquisition of assets of Bedford Laboratories ("Bedford") in July 2014 and agreed to acquire substantially all of the assets of the Ben Venue manufacturing site, significantly enhancing the long term strength of our global Injectables business
Continued to build our global product portfolio through new product introductions across all countries and markets - launched 49 products and received 140 product approvals
Interim dividend of 7.0 cents per share, in line with the first half of 2013
Declared a special dividend of 4.0 cents per share, reflecting the exceptionally strong market opportunities captured by our US businesses in the first half of 2014
